Chondrochymal (allogeneic bone marrow derived mesenchymal stem cells) / Taiwan Bio - LARVOL DELTA

Chondrochymal® for Subjects With Knee Osteoarthritis (Knee OA) (clinicaltrials.gov) - P2 | N=72 | Completed | Sponsor: Taiwan Bio Therapeutics Inc. | Active, not recruiting ➔ Completed

Trial completion • Immunology • Osteoarthritis • Pain • Rheumatology

Chondrochymal® for Subjects With Knee Osteoarthritis (Knee OA) (clinicaltrials.gov) - P2 | N=72 | Active, not recruiting | Sponsor: Taiwan Bio Therapeutics Inc. | Trial completion date: Mar 2025 ➔ Jun 2025

Trial completion date • Immunology • Osteoarthritis • Pain • Rheumatology

Chondrochymal® for Subjects With Knee Osteoarthritis (Knee OA) (clinicaltrials.gov) - P2 | N=72 | Active, not recruiting | Sponsor: Taiwan Bio Therapeutics Co., Ltd. | Recruiting ➔ Active, not recruiting | Phase classification: P2b ➔ P2 | Trial completion date: Sep 2024 ➔ Mar 2025 | Trial primary completion date: Sep 2023 ➔ Dec 2023

Enrollment closed • Phase classification • Trial completion date • Trial primary completion date • Immunology • Osteoarthritis • Pain • Rheumatology

Taibao's new drug for osteoarthritis completed Phase II clinical trial [Google translation] (stock.yahoo) - "Taibao (6892) announced...that the Phase II clinical trial of Chondrochymal, a new non-genetically modified bone marrow mesenchymal stem cell drug, for the treatment of osteoarthritis has been completed and the case has been accepted. After the clinical data results are released, it will apply for the Phase III clinical trial."

Trial completion • CNS Disorders • Osteoarthritis • Pain

Taibao Osteoarthritis New Drug Completed Phase II Clinical Case and Applied for Conditional Permission [Google translation] (stock.yahoo) - "Huang Zhiyuan...said at the shareholder meeting on the 27th that benefiting from the sprint performance of the four major strategies, he is optimistic about this year's operating performance. Chondrochymal, a new non-genetically modified cell drug for the treatment of knee degenerative arthritis, has recently completed Phase IIb After the clinical trial is accepted, the company will strive for the opportunity to apply for conditional approval for marketing."

Non-US regulatory • Trial completion • CNS Disorders • Immunology • Osteoarthritis • Pain

Chondrochymal® for Subjects With Knee Osteoarthritis (Knee OA) (clinicaltrials.gov) - P2b; N=70; Recruiting; Sponsor: Taiwan Bio Therapeutics Co., Ltd.; Not yet recruiting ➔ Recruiting

Enrollment open • Immunology • Osteoarthritis • Pain • Rheumatology • CRP • MRI

Chondrochymal® for Subjects With Knee Osteoarthritis (Knee OA) (clinicaltrials.gov) - P2b; N=70; Not yet recruiting; Sponsor: Taiwan Bio Therapeutics Co., Ltd.

Clinical • New P2b trial • Immunology • Osteoarthritis • Pain • Rheumatology • CRP • MRI

Allogeneic Bone Marrow MSC Therapy for Knee Osteoarthritis (clinicaltrials.gov) - P1/2; N=18; Completed; Sponsor: Taipei Veterans General Hospital, Taiwan; Recruiting ➔ Completed

Clinical • Trial completion • Immune Modulation • Immunology • Osteoarthritis • Pain • Rheumatology • MRI